Bora Pharmaceuticals Past Earnings Performance
Past criteria checks 5/6
Bora Pharmaceuticals has been growing earnings at an average annual rate of 49.6%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 53.8% per year. Bora Pharmaceuticals's return on equity is 26.1%, and it has net margins of 21.3%.
Key information
49.6%
Earnings growth rate
47.4%
EPS growth rate
Pharmaceuticals Industry Growth | 18.5% |
Revenue growth rate | 53.8% |
Return on equity | 26.1% |
Net Margin | 21.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Mar 14Recent updates
Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Apr 10Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt
Apr 08Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Mar 14Is Bora Pharmaceuticals (GTSM:6472) A Risky Investment?
Apr 30Are Strong Financial Prospects The Force That Is Driving The Momentum In Bora Pharmaceuticals Co., LTD.'s GTSM:6472) Stock?
Mar 17Bora Pharmaceuticals (GTSM:6472) Has Rewarded Shareholders With An Exceptional 695% Total Return On Their Investment
Feb 17New Forecasts: Here's What Analysts Think The Future Holds For Bora Pharmaceuticals Co., LTD. (GTSM:6472)
Jan 27Bora Pharmaceuticals (GTSM:6472) Takes On Some Risk With Its Use Of Debt
Jan 19We're Not So Sure You Should Rely on Bora Pharmaceuticals's (GTSM:6472) Statutory Earnings
Dec 29Are Robust Financials Driving The Recent Rally In Bora Pharmaceuticals Co., LTD.'s (GTSM:6472) Stock?
Dec 09Revenue & Expenses BreakdownBeta
How Bora Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 14,200 | 3,030 | 1,444 | 298 |
30 Sep 23 | 16,293 | 2,868 | 1,344 | 272 |
30 Jun 23 | 15,942 | 2,704 | 1,212 | 238 |
31 Mar 23 | 14,158 | 2,252 | 1,056 | 176 |
31 Dec 22 | 10,494 | 1,392 | 862 | 129 |
30 Sep 22 | 6,346 | 1,128 | 687 | 57 |
30 Jun 22 | 4,811 | 697 | 586 | 38 |
31 Mar 22 | 4,650 | 594 | 571 | 41 |
31 Dec 21 | 4,900 | 750 | 585 | 41 |
30 Sep 21 | 4,418 | 1,045 | 637 | 40 |
30 Jun 21 | 3,626 | 963 | 578 | 39 |
31 Mar 21 | 2,794 | 868 | 507 | 37 |
31 Dec 20 | 1,800 | 578 | 441 | 37 |
30 Sep 20 | 1,523 | 191 | 300 | 37 |
30 Jun 20 | 1,513 | 232 | 293 | 38 |
31 Mar 20 | 1,521 | 262 | 280 | 39 |
31 Dec 19 | 1,529 | 305 | 259 | 40 |
30 Sep 19 | 1,517 | 355 | 217 | 38 |
30 Jun 19 | 1,492 | 283 | 236 | 41 |
31 Mar 19 | 1,515 | 267 | 227 | 41 |
31 Dec 18 | 1,372 | 443 | 220 | 38 |
30 Sep 18 | 1,107 | 351 | 200 | 36 |
30 Jun 18 | 846 | 330 | 141 | 28 |
31 Mar 18 | 525 | 274 | 116 | 23 |
31 Dec 17 | 358 | 14 | 87 | 20 |
30 Sep 17 | 323 | 17 | 81 | 19 |
30 Jun 17 | 297 | 22 | 74 | 18 |
31 Mar 17 | 291 | 24 | 73 | 18 |
31 Dec 16 | 283 | 25 | 71 | 18 |
30 Sep 16 | 273 | 23 | 68 | 18 |
30 Jun 16 | 260 | 18 | 69 | 18 |
31 Mar 16 | 247 | 26 | 67 | 17 |
31 Dec 15 | 238 | 34 | 65 | 17 |
30 Sep 15 | 236 | 30 | 65 | 13 |
30 Jun 15 | 234 | 28 | 68 | 12 |
31 Mar 15 | 226 | 23 | 65 | 10 |
31 Dec 14 | 218 | 17 | 62 | 9 |
30 Sep 14 | 182 | 16 | 54 | 9 |
30 Jun 14 | 154 | 16 | 44 | 8 |
31 Mar 14 | 123 | 10 | 41 | 6 |
31 Dec 13 | 93 | 4 | 37 | 3 |
Quality Earnings: 6472 has a large one-off loss of NT$1.0B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 6472's current net profit margins (21.3%) are higher than last year (13.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6472's earnings have grown significantly by 49.6% per year over the past 5 years.
Accelerating Growth: 6472's earnings growth over the past year (117.7%) exceeds its 5-year average (49.6% per year).
Earnings vs Industry: 6472 earnings growth over the past year (117.7%) exceeded the Pharmaceuticals industry -15%.
Return on Equity
High ROE: 6472's Return on Equity (26.1%) is considered high.